Shares

34 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.78 - $14.19 $7.34 Million - $13.4 Million
942,983 New
942,983 $7.56 Million
Q4 2023

Feb 09, 2024

BUY
$3.3 - $8.89 $3.7 Million - $9.96 Million
1,120,457 New
1,120,457 $9.11 Million
Q3 2023

Nov 13, 2024

BUY
$4.44 - $8.79 $4.97 Million - $9.85 Million
1,120,457 New
1,120,457 $5.1 Million
Q3 2023

Nov 13, 2023

SELL
$4.44 - $8.79 $6.2 Million - $12.3 Million
-1,396,357 Closed
0 $0
Q2 2023

Aug 14, 2024

BUY
$5.36 - $9.06 $951,260 - $1.61 Million
177,474 Added 18.82%
1,120,457 $7.89 Million
Q2 2023

Aug 14, 2023

SELL
$5.36 - $9.06 $7.26 Million - $12.3 Million
-1,354,235 Closed
0 $0
Q1 2023

May 15, 2024

BUY
$5.53 - $8.22 $13.5 Million - $20.1 Million
2,440,057 New
2,440,057 $14.9 Million
Q4 2022

Feb 14, 2023

BUY
$5.62 - $10.0 $16.7 Million - $29.7 Million
2,974,857 New
2,974,857 $19 Million
Q3 2022

Nov 13, 2023

BUY
$9.53 - $13.11 $13.3 Million - $18.3 Million
1,396,357 New
1,396,357 $13.4 Million
Q2 2022

Aug 14, 2023

BUY
$6.38 - $18.33 $8.64 Million - $24.8 Million
1,354,235 New
1,354,235 $15 Million
Q1 2022

May 12, 2023

SELL
$12.38 - $19.1 $20.1 Million - $31 Million
-1,621,118 Reduced 54.49%
1,353,739 $22.5 Million
Q1 2022

May 09, 2022

SELL
$12.38 - $19.1 $16.1 Million - $24.9 Million
-1,301,450 Closed
0 $0
Q4 2021

Mar 09, 2022

BUY
$16.55 - $27.63 $21.5 Million - $36 Million
1,301,450 New
1,301,450 $24.8 Million
Q3 2021

Nov 14, 2022

BUY
$20.35 - $26.63 $25.2 Million - $33 Million
1,238,198 New
1,238,198 $30.5 Million
Q3 2021

Nov 05, 2021

SELL
$20.35 - $26.63 $24.1 Million - $31.6 Million
-1,185,673 Closed
0 $0
Q2 2021

Aug 15, 2022

BUY
$16.33 - $33.07 $19.4 Million - $39.2 Million
1,185,673 New
1,185,673 $30.9 Million
Q2 2021

Aug 10, 2021

SELL
$16.33 - $33.07 $20 Million - $40.5 Million
-1,224,416 Closed
0 $0
Q1 2021

May 09, 2022

BUY
$28.67 - $52.59 $35.1 Million - $64.4 Million
1,224,416 New
1,224,416 $38.8 Million
Q1 2021

May 07, 2021

SELL
$28.67 - $52.59 $42.2 Million - $77.4 Million
-1,472,631 Closed
0 $0
Q4 2020

Mar 02, 2021

BUY
$28.04 - $50.26 $41.3 Million - $74 Million
1,472,631 New
1,472,631 $68.3 Million
Q4 2020

Feb 10, 2021

SELL
$28.04 - $50.26 $42.9 Million - $76.9 Million
-1,530,154 Closed
0 $0
Q3 2020

Nov 12, 2021

BUY
$27.75 - $36.3 $42.5 Million - $55.5 Million
1,530,154 New
1,530,154 $50.4 Million
Q3 2020

Nov 10, 2020

SELL
$27.75 - $36.3 $40.2 Million - $52.6 Million
-1,449,779 Closed
0 $0
Q2 2020

Aug 13, 2021

BUY
$27.21 - $41.0 $39.4 Million - $59.4 Million
1,449,779 New
1,449,779 $39.8 Million
Q2 2020

Aug 07, 2020

SELL
$27.21 - $41.0 $35.6 Million - $53.7 Million
-1,308,979 Closed
0 $0
Q1 2020

May 07, 2021

BUY
$19.54 - $38.85 $25.6 Million - $50.9 Million
1,308,979 New
1,308,979 $39.2 Million
Q1 2020

May 08, 2020

SELL
$19.54 - $38.85 $25.6 Million - $50.9 Million
-1,308,979 Closed
0 $0
Q4 2019

Mar 03, 2020

BUY
$17.95 - $29.41 $23.5 Million - $38.5 Million
1,308,979 New
1,308,979 $36.2 Million
Q4 2019

Feb 12, 2020

SELL
$17.95 - $29.41 $10.9 Million - $17.9 Million
-607,429 Closed
0 $0
Q3 2019

Nov 13, 2020

BUY
$17.99 - $26.0 $10.9 Million - $15.8 Million
607,429 New
607,429 $11.1 Million
Q3 2019

Nov 08, 2019

SELL
$17.99 - $26.0 $359,799 - $520,000
-20,000 Closed
0 $0
Q2 2019

Aug 13, 2020

BUY
$9.78 - $24.52 $195,600 - $490,400
20,000 New
20,000 $490,000
Q2 2019

Aug 09, 2019

SELL
$9.78 - $24.52 $195,600 - $490,400
-20,000 Closed
0 $0
Q4 2018

Mar 04, 2019

BUY
$7.51 - $11.93 $150,200 - $238,600
20,000 New
20,000 $177,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $923M
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.